Overview

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Status:
Terminated

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim